As of 6 Nov 2026, ORTIN GLOBAL is loss-making on a trailing 12-month basis, with a net loss of ₹0.90 Cr, so it has no P/E ratio. The share price is ₹13.02, 39% below its 52-week high. Sales fell 74% a year over 3 years. Debt is 0.81× equity. It is a small-cap company with a market cap of ₹11 Cr, ranked 149th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 22% over the past year.
- ₹13.92
- ₹13.92
- ₹13.00
- ₹13.90
- 14K
Health check
- ReturnsIn line
+21.7% over a year, better than 3 of 7 peers.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- GrowthShrinking
Sales −74.4% a year over 3 years.
- ProfitabilityNegative
ROCE -32.2% vs peer median 17.9%.
- Balance sheetStretched
Debt 0.81× equity, operating profit doesn’t cover interest.
- Red flags5 to check
Loss-making over the last twelve months.
Small cap
Defensive
Key metrics
- Market cap
- ₹11 Cr
- Small cap
- P/E
- n/a
- Industry 28.7
- Price to book
- 9.79
- Peers 4.99
- Dividend yield
- 0.00%
- ROE
- −46.1%
- Peers 14.7%
- ROCE
- −32.2%
- Peers 17.9%
- Debt to equity
- 0.81
- Debt ₹1.01 Cr
- EPS (TTM)
- −₹1.12
- Face value ₹10
- OPM (TTM)
- −1234.4%
- Net margin 0.0%
- Sales growth
- −70.9%
- Latest quarter vs a year ago
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- 297.39
- EV/EBITDA −9.0
Strengths and risks
Risks to check
- Loss-making over the last twelve months.
- Return on equity is low at −46.1%.
- Quarterly sales down 70.9% on a year ago.
- 39% below its 52-week high.
- Interest coverage of only −1725.3×.
About ORTIN GLOBAL
Ortin Global Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders; formulations, such as anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helmenthetics, analgesics and antipyretics, anti-biotics-quinolones, anti-biotic-pencillins, antifungal, cephalosporins,…
- Headquarters
- Hyderabad
- Employees
- 8
- Sector
- Healthcare
- ISIN
- INE749B01020
- Website
- ortinlabsindia.com
Price range
- Avg volume (3M)
- 11.9K
- 1-year return
- plus 21.7%
- From 52-week high
- minus 38.9%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.86% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.29% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.80% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.58% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.92% | minus 6.6% |
| ORTINGLOBEORTIN GLOBAL | 13.02 | minus 6.33% | 11 | – | 9.79 | – | −84.2% | −1234.4% | −74.4% | – | 0.00% | plus 21.7% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.58% | 22.8% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | |
| 0.2 | 0.5 | 0.1 | 0 | 0.3 | |
| −0.2 | −0.5 | −0 | −0 | −0.3 | |
| −408.3% | −3581.4% | −401.6% | −21.5% | −2881.9% | |
| 0 | 0 | 0 | 0 | 0 | |
| 0 | 0 | – | 0 | – | |
| – | 0 | 0 | 0 | 0 | |
| −0.2 | −0.5 | −0 | −0 | −0.3 | |
| −7.7% | 0.0% | −8.6% | −4.5% | −1.0% | |
| −0.2 | −0.5 | −0.1 | −0 | −0.3 | |
| -0.22 | -0.62 | -0.07 | -0.01 | -0.42 |
Profit & loss
- Sales CAGR 3Y
- −74.4%
- ROE
- −46.1%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 6 | 2.1 | 0.3 | 0.1 | |
| – | minus 64.9% | minus 83.8% | minus 70.6% | |
| 5.5 | 6.4 | 1.2 | 1.1 | |
| 0.5 | −4.2 | −0.9 | −1 | |
| 8.6% | −200.9% | −258.2% | −1030.0% | |
| −0 | 0.2 | 0 | 0.3 | |
| 0.3 | 0.5 | 0 | 0 | |
| 0.3 | 0.2 | 0 | 0 | |
| −0 | −2.3 | 0 | 0 | |
| −0.1 | −7.1 | −0.8 | −0.7 | |
| 15.3% | −13.7% | −1.1% | −2.4% | |
| −0.1 | −8 | −0.8 | −0.7 | |
| -0.12 | -9.89 | -1.04 | -0.91 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 8.1 | 8.1 | 8.1 | 8.1 | |
| 2.7 | −5.3 | −6.2 | −6.9 | |
| 6.4 | 1.8 | 0.3 | 1 | |
| 3.9 | 2 | 1.6 | 2.4 | |
| 21.2 | 6.7 | 3.8 | 4.6 | |
| 14.4 | 0 | 0 | 0 | |
| 0.4 | – | – | – | |
| 0.2 | 0.5 | 0.4 | 0.6 | |
| 6.2 | 6.2 | 3.4 | 4 | |
| 21.2 | 6.7 | 3.8 | 4.6 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| −0.3 | −4.8 | −0.4 | −0.6 | |
| 0 | 12 | −0 | 0 | |
| 0.9 | −3.5 | 0.3 | 0.8 | |
| 0.7 | 3.7 | −0.1 | 0.2 | |
| −0 | – | −0 | – | |
| −0.3 | −4.8 | −0.4 | −0.6 |
Shareholding pattern
- Promoters1.24%
- Public98.76%
| Quarter | Split | Promoters | Public | Promoter change |
|---|---|---|---|---|
| 30 Sep 2026 | 1.24% | 98.76% | plus 0.01 | |
| 30 Jun 2026 | 1.23% | 98.77% | 0.00 | |
| 31 Mar 2026 | 1.23% | 98.77% | 0.00 | |
| 31 Dec 2025 | 1.23% | 98.77% | 0.00 | |
| 30 Sep 2025 | 1.23% | 98.77% | – |
Major shareholders
Filings & events
News
No recent news coverage found.